MYD88 and cancer: Previously, our lab described the development of a synthetic ligand-inducible MyD88/CD40 (“MC”) fusion protein, comprising signaling elements from MyD88 and CD40, two FKBP12-based ligand-binding domains, and a myristoylation membrane localization domain, as an adjuvant for cancer vaccines [10].